Abstract
Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential ‘antioxidant’ activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.
Keywords: Glucagon-like peptide-1, oxidative stress, diabetes, diabetic complications.
Current Diabetes Reviews
Title:Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies
Volume: 12 Issue: 4
Author(s): Karen Ekkelund Petersen, Günaj Rakipovski, Kirsten Raun and Jens Lykkesfeldt
Affiliation:
Keywords: Glucagon-like peptide-1, oxidative stress, diabetes, diabetic complications.
Abstract: Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential ‘antioxidant’ activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.
Export Options
About this article
Cite this article as:
Petersen Ekkelund Karen, Rakipovski Günaj, Raun Kirsten and Lykkesfeldt Jens, Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies, Current Diabetes Reviews 2016; 12 (4) . https://dx.doi.org/10.2174/1573399812666150918150608
DOI https://dx.doi.org/10.2174/1573399812666150918150608 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Tumor Specific Imaging Using Tc-99m and Ga-68 Labeled Radiopharmaceuticals
Current Medical Imaging Diagnostic Tools for Diabetic Sensorimotor Polyneuropathy
Current Diabetes Reviews Humanin; A Defender Against Alzheimers Disease?
Recent Patents on CNS Drug Discovery (Discontinued) Patent Review
Combinatorial Chemistry & High Throughput Screening Chalcones and <i>Bis</i>-Chalcones Analogs as DPPH and ABTS Radical Scavengers
Letters in Drug Design & Discovery Insight on the Pathogenesis of Diabetic Nephropathy from the Study of Podocyte and Mesangial Cell Biology
Current Diabetes Reviews Intranasal Lipid Nanoparticles for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Advances in the Chemistry of Saccharins: From Synthetic Novelties Towards Biologically Active Compounds
Current Medicinal Chemistry Gene Therapy in the Management of Parkinson’s Disease: Potential of GDNF as a Promising Therapeutic Strategy
Current Gene Therapy Davunetide: Peptide Therapeutic in Neurological Disorders
Current Medicinal Chemistry Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry Synthesis, Crystal Structure, Anti-inflammatory and Anti-hyperglycemic Activities of Novel 3,4-Disubstituted 1,2,4-Triazol-5(4H)-one Derivatives
Medicinal Chemistry Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Microfluidic Methods for Non-Viral Gene Delivery
Current Gene Therapy Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews Implication of Rho GTPases in Neurodegenerative Diseases
Current Drug Targets Oxidative Stress and Skeletal Muscle Dysfunction with Aging
Current Aging Science Towards Retinoid Therapy for Alzheimers Disease
Current Alzheimer Research